期刊文献+

舒洛地特原料药安全性检查法研究 被引量:3

Safety Test of Active Pharmaceutical Ingredients of Sulodexide
下载PDF
导出
摘要 目的探讨舒洛地特原料药的安全性。方法按2015年版《中国药典(四部)》通则方法及要求,对舒洛地特原料药过敏反应、降压物质和异常毒性检查法进行研究。结果舒洛地特原料药的过敏反应检查限值为500LSU/kg,降压物质检查限值为50LSU/kg,异常毒性检查限值为2000LSU/kg。结论该研究为制订舒洛地特质量标准提供了依据。 Objective To investigate the safety of active pharmaceutical ingredients(API)of sulodexide.Methods According to the requirements and methods of the general rule in the Chinese Pharmacopoeia(2015 edition,volumeⅣ),allergic response test,depressor substances test,and the abnormal toxicity test of API of sulodexide were studied.Results The limit value of allergic response test was 500 LSU/kg and the limit value of depressor substances test was 50 LSU/kg,the limit value of abnormal toxicity test was 2 000 LSU/kg.Conclusion This study can provide a basis for the formulation of the quality standard of sulodexide.
作者 张娟 魏霞 李水仙 祝清芬 ZHANG Juan;WEI Xia;LI Shuixian;ZHU Qingfen(Shandong Institute for Food and Drug Control,Jinan,Shandong,China 250101)
出处 《中国药业》 CAS 2019年第14期22-25,共4页 China Pharmaceuticals
关键词 舒洛地特 原料药 过敏反应 降压物质 异常毒性 安全性检查 sulodexide active pharmaceutical ingredients allergic response depressor substances abnormal toxicity safety test
  • 相关文献

参考文献8

二级参考文献68

  • 1Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy[J].Drugs, 2007,67(18):2681 --2696.
  • 2Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy[J]. Treat Endocrinol, 2006,5 (4) : 211 --222.
  • 3Noti C, Seeberger PH. Chemical approaches to define the structure-activity relationship of heparinlike glycosaminoglycans[J]. Chem Biol, 2005, 12 (7) :731--756.
  • 4Ofosu FA. Pharmacological actions of sulodexide [J].Semin Thromb Hemost, 1998,24(2):127-- 138.
  • 5Nenci GG. Dermatan sulphate as an antithrombotic drug[J]. Pathophysiol Haemost Thromh, 2002,32 (5/6) :303--307.
  • 6Fabiana AM, Giaquinta RD, Lazzari M. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate [J]. Thromb Res, 2008,122(1) :109--116.
  • 7Cristofori M, Mastaccbi R, Barbanti M, et al Pharmacokinetics and distribution of a fluoresceinat ed glycosaminoglycan, sulodexide, in rats. Part I Pharmacokinetics in rats [J]. Arzneimittelfors chung, 1985,35(10) :1513--1516.
  • 8Harenberg J. Review of pharmacodynamies, phar macokinetics, and therapeutic properties of sulodexide[J]. MedResRev, 1998,18(1):1--20.
  • 9Ceriello A, Quatraro A, Marchi E. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: Effects of the glycosaminoglycan sulodexide[J]. Diabete Metab, 1993, 19(2) :225--229.
  • 10Baglin TP, Carrell RW, Church FC,et al. Crystal structures of native and thrombincomplexed heparin cofactor II reveal a multistep allosteric mechanism [J]. Proc Natl Acad Sci, 2002,99(17): 11079-- 11084.

共引文献33

同被引文献28

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部